Previous 10 | Next 10 |
MALVERN, Pa., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug produ...
It has been almost three years since we checked in on a small specialty drug manufacturer named Recro Pharma. A lot has happened since then and the company beat the consensus with its last quarterly results and fourth quarter numbers are on tap. We update our investment thesis on ...
Company Names CDMO Industry Thought Leader, Jim Miller, to Board of Directors and Selects Ryan D. Lake as Dedicated Chief Financial Officer Recent Appointments, including CEO David Enloe, Provide Experienced Leadership to Drive Growth for Company’s Unique End-to-End CDMO ...
MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage...
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage...
Are These Penny Stocks On Your Buy List? If you’re looking for penny stocks to buy right now, where do you search first? Especially on a weekend when the market isn’t open, company info can play a bigger role. Without active trading, intra-day technical ana...
Recro Pharma, Inc. (REPH) Q3 2020 Earnings Conference Call November 09, 2020, 08:00 ET Company Participants Claudia Styslinger - Argot Partners Geraldine Henwood - President, CEO & Director Ryan Lake - CFO Conference Call Participants Leland Gershell - Oppenheimer Jacob Johnson - Stephens...
Recro Pharma ([[REPH]] +21.2%) Q3 results:Revenue $19.3M (+24% Q/Q), beats consensus by $2.96M.Revenue decreased $6M compared to previous year same quarter as a result of customer ordering patterns in the prior year and the loss of Verapamil SR market share.Interest expense was $14.7M vs. $13...
Image source: The Motley Fool. Recro Pharma (NASDAQ: REPH) Q3 2020 Earnings Call Nov 09, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Recro Pharma (REPH) Q3 2020 Earnings Call Transcript
Recro Pharma (REPH): Q3 GAAP EPS of -$0.09 beats by $0.11.Revenue of $19.29M (-23.6% Y/Y) beats by $2.96M.Press Release For further details see: Recro Pharma EPS beats by $0.11, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...